Status:
COMPLETED
Dose Ranging and Dose Frequency of LIPO-102
Lead Sponsor:
Neothetics, Inc
Conditions:
Subcutaneous Adipose Tissue Reduction
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Dose Ranging and Dose Frequency of LIPO-102
Eligibility Criteria
Inclusion
- Male or non pregnant female
- Good general health
- Sufficient abdominal fat for injections
- Signed informed consent
Exclusion
- Known hypersensitivity to study drugs
- Treatment with an investigational agent within 30 days of first dose
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00918814
Start Date
June 1 2009
End Date
February 1 2010
Last Update
March 6 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
San Diego, California, United States
2
Baltimore, Maryland, United States